Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Vomiting 2Uterine Cervical Neoplasms 2Nausea 2Condylomata Acuminata 2Breast Neoplasms 2Sezary Syndrome 1Renal Insufficiency 1Osteoarthritis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Kidney Failure, Chronic 1Cancer Pain 1Bone Neoplasms 1Adenomatous Polyposis Coli 1

Interventions

Cisplatin 178Paclitaxel 79Radiotherapy 76Carboplatin 70Brachytherapy 69pembrolizumab 63Bevacizumab 40Gemcitabine 28Radiation 27Topotecan 26Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 25Nivolumab 22Colposcopy 22human papillomavirus vaccine, L1 type 16, 18 21Magnetic Resonance Spectroscopy 21Drug Therapy 20atezolizumab 19Platinum 19Papillomavirus Vaccines 18Radiotherapy, Intensity-Modulated 17Docetaxel 17Taxes 16Cyclophosphamide 16Biopsy 16Early Intervention, Educational 151,2-diaminocyclohexaneplatinum II citrate 15Methods 14Blood Specimen Collection 14fludarabine 13Injections 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Uterine Cervical Neoplasms × Duration of Therapy × Clear all
NCT00092482 2017-03-22

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 3 Completed
3,882 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00517309 2017-03-22

FUTURE

Merck Sharp & Dohme LLC

Phase 3 Completed
1,877 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

Data powered by HemOnc (CC BY 4.0) Colophon âš¡